Sept 26 (Reuters) - The U.S. Food and Drug

Administration on Thursday alerted patients and healthcare

professionals about the withdrawal of Pfizer's ( PFE ) sickle

cell disease treatment Oxbryta.

Pfizer ( PFE ) said late on Wednesday it was pulling the drug from

all markets due to risk of a painful complication and death.

The FDA said it was conducting a safety review of

postmarketing clinical data for the drug, and will also review

real world registry studies.